Personalized pre-surgery treatment for HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with HER2-positive breast cancer that has not spread to distant organs (stage I to III).
- Your tumor is at least 1.5 cm in size.
- You have not had any previous chemotherapy, targeted therapy, radiation, or hormone therapy for this cancer.
- Your heart, liver, kidneys, and blood counts are within acceptable ranges.
- You are willing to follow the study plan and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.